Claudia Zylberberg, PhD, is a biotechnology entrepreneur, immunologist, and board leader operating at the intersection of advanced therapies, manufacturing strategy, and AI-enabled healthcare infrastructure. She is the founder and chair of the board of Akron Bio, a cGMP ancillary materials company supporting global cell and gene therapy developers. She is also co-founder and chair of ARScience Bio, advancing cytokine-based immune therapeutics, and co-founder of Kosten Digital, an AI implementation and integration firm focused on healthcare and life sciences digital transformation across the U.S., LATAM, and Europe.

An inventor with issued patents and author of peer-reviewed scientific publications, Dr. Zylberberg brings deep expertise in translational science, commercialization strategy, decentralized manufacturing models, and digital orchestration of complex healthcare systems. Her work centers on advancing scalable, compliant, and economically sustainable models to expand global access to next-generation therapies.